Overall, a 33% increased risk of major bleeding was seen, with risk highest during the first 30 days of concomitant use and persistent, but lower, after 6 months.
Anticoagulation and antiplatelet therapy appeared equally effective in reducing risk of recurrent stroke following cryptogenic stroke in persons with evidence of atrial cardiopathy.
In apixaban-treated participants, risk of stroke or systemic embolism was reduced by 37%; the risk of disability or fatal stroke declined by 49%, but with noted bleeding risk.